Obesity Pills: Eli Lilly, Novo Nordisk US Launch Near

Here’s a breakdown of the key information from the provided article excerpt:

Main Focus: The upcoming rivalry between Eli Lilly (LLY) and novo Nordisk (NVO) in the oral weight-loss medication market. Both companies are preparing to launch pills in the U.S. next year.

Key Points:

* Oral vs.Injectable: ⁢The pills will make GLP-1 medications ⁣(currently primarily administered via weekly shots) ⁢more accessible to a wider audience.
* Lilly’s Pill Results: A recent trial of Lilly’s pill (orforglipron) showed less weight loss than analysts expected, raising questions about adoption rates.
* Head-to-Head Trial: ‍ Lilly and Novo are conducting a head-to-head ⁣trial to directly compare their pills. While primarily focused on blood ⁣sugar reduction in Type 2 diabetes patients, it will also measure weight ‍loss. Lilly’s CSO, ⁣Dan Skovronsky, expresses confidence in their pill’s performance.
* Differing Opinions: Novo’s CSO, Martin Holst Lange, believes their data already demonstrates the effectiveness of their pill.
* Drug Differences: Novo’s pill is an oral version of Wegovy (their existing shot). Lilly’s pill (orforglipron) is a new drug, distinct from ‍Zepbound (their shot), which is considered the “gold standard” for efficacy.

In essence, the article sets the stage for a competitive battle in the weight-loss drug market, highlighting the ⁢uncertainties surrounding the effectiveness‍ and adoption of oral medications compared to the established injectable options.